Results 21 to 30 of about 140,938 (293)
Detection of activating mutations in RAS/RAF/MEK/ERK and JAK/STAT signaling pathways [PDF]
Терапевтический архив, 2020 Issue.The study of activating mutations (NRAS,KRAS,FLT3,JAK2,CRLF2genes) of RAS/RAF/MEK/ERK and JAK/STAT signaling pathways in B-cell acute lymphoblastic leukemia (B-ALL) in adult patients which are included in Russian multicenter clinical trials ...
K. I. Zarubina +13 more
doaj +1 more source
MAPK and AKT pathway inactivation by cetuximab-KRAS- and cetuximab-PIK3CA-esiRNA treatment. [PDF]
, 2018 Tumor lysate samples from xenograft experiments were processed for SDS PAGE and probed in Western blots for expression of KRAS downstream MAPK pathway effector phospho-ERK and PIK3CA downstream phospho-AKT along with their unphosphorylated (total ...
Wolfgang Hartmann (38453) +9 more
core +1 more source
Roczniki Historyczne, 2014 „Wie sollen die Füchse im Weinberg des Herrn gefangen werden?” Antihäretische Inhalte in den Predigten Bernhards von Clairvaux und Helinands von Froidmont Zusammenfassung Seit der Mitte des 12.
Paweł Kras
doaj +1 more source
Nesting of Eurasian Crag Martin (Ptyonoprogne rupestris) in the Malá Fatra Mts. in Slovakia
Tichodroma, 2022 We detected occurrence and nesting of Eurasian Craig Martin (Ptyonoprogne rupestris) for the first time in Slovakia. One nesting pair with four juveniles was detected during the 2022 nesting season in the Malá Fatra mountains.
Štefan Matis +2 more
doaj +1 more source
Molecular genetic testing in colon cancer: clinical aspects
Alʹmanah Kliničeskoj Mediciny, 2022 Molecular genetic diagnostics is an essential element to plan for management of colorectal cancer (CRC) patients. The choice of systemic treatment for CRC is impossible without molecular testing of the tumor.
Aleksandr S. Martianov +3 more
doaj +1 more source
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors
OncoImmunology, 2021 T-cell receptor (TCR) redirected T cells are considered as the next generation of care for the treatment of numerous solid tumors. KRAS mutations are driver neoantigens that are expressed in over 25% of all cancers and are thus regarded as ideal targets ...
Pierre Dillard +7 more
doaj +1 more source
Biomarker series: KRAS- A narrative review
Cancer Research, Statistics, and Treatment, 2021 Non-small cell lung cancer (NSCLC) has emerged as the poster child of molecular medicine. Kirsten rat sarcoma (KRAS)-mutated NSCLC is a common yet heterogeneous entity with distinct clinical and prognostic characteristics.
Ullas Batra, Shrinidhi Nathany
doaj +1 more source
Velocity feedback control with a flywheel proof mass actuator [PDF]
, 2017 This paper presents four new proof mass actuators to be used in velocity feedback control systems for the control of vibrations of machines and flexible structures.
KRAS, Aleksander Stefan +3 more
core +1 more source
Targeting PDE6D for inhibiting KRAS: A computational approach [PDF]
, 2022 Lung cancer is the cancer of the lung\u27s epithelial cells typically characterized by difficult breathing, chest pain, blood-stained coughs, headache, and weight loss. If left unmanaged, lung cancer can spread to other body parts.
Gbenga, Dairo +3 more
core +1 more source
Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy
Chinese Journal of Lung Cancer, 2022 Proteolysis targeting chimeria (PROTAC) degrades target proteins by utilizing the ubiquitin-proteasome pathway, subverting the concept of traditional small molecule inhibitors.
Lin JIANG +4 more
doaj +1 more source